Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study

Edmund Laua Royal Prince Alfred Hospital, University of Sydney, Camperdown, Australia

Eugene Kotlyarb St. Vincent’s Hospital, Sydney, Australia

Yogeshwar Makanjic Janssen Pharmaceuticals Asia Pacific, Singapore, SingaporeCorrespondence[email protected]

https://orcid.org/0009-0003-3131-5558

Dae Young Yuc Janssen Pharmaceuticals Asia Pacific, Singapore, Singapore

Jin Yu Tanc Janssen Pharmaceuticals Asia Pacific, Singapore, Singapore

Jeremy Casorsod Prospection, Haymarket, Australia

Mahsa H. Kouhkamarid Prospection, Haymarket, Australia

Sooyeol Limd Prospection, Haymarket, Australia

David Bin-Chia Wuc Janssen Pharmaceuticals Asia Pacific, Singapore, Singapore;e Saw Swee Hock School of Public Health, National University of Singapore, Singapore, SingaporeCorrespondence[email protected]

https://orcid.org/0000-0003-1091-5792

Paul Bloomfieldc Janssen Pharmaceuticals Asia Pacific, Singapore, Singapore

show all

Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date